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Background: N-methyl-d-aspartate receptor (NMDAR) dysfunction is thought to contribute to the pathophysiology of 
schizophrenia. Accordingly, NMDAR antagonists such as phencyclidine (PCP) are used widely in experimental animals to 
model cognitive impairment associated with this disorder. However, it is unclear whether PCP disrupts the structural integrity 
of brain areas relevant to the profile of cognitive impairment in schizophrenia.
Methods: Here we used high-resolution magnetic resonance imaging and voxel-based morphometry to investigate structural 
alterations associated with sub-chronic PCP treatment in rats.
Results: Sub-chronic exposure of rats to PCP (5 mg/kg twice daily for 7 days) impaired sustained visual attention on a 
5-choice serial reaction time task, notably when the attentional load was increased. In contrast, sub-chronic PCP had 
no significant effect on the attentional filtering of a pre-pulse auditory stimulus in an acoustic startle paradigm. Voxel-
based morphometry revealed significantly reduced grey matter density bilaterally in the hippocampus, anterior cingulate 
cortex, ventral striatum, and amygdala. PCP-treated rats also exhibited reduced cortical thickness in the insular cortex.
Conclusions: These findings demonstrate that sub-chronic NMDA receptor antagonism is sufficient to produce highly-
localized morphological abnormalities in brain areas implicated in the pathogenesis of schizophrenia. Furthermore, PCP 
exposure resulted in dissociable impairments in attentional function.
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Introduction
Deficits in cognition are a hallmark of schizophrenia. The 
Measurement and Treatment Research to Improve Cognitive 
in Schizophrenia Initiative (MATRICS) and the CNTRICS group 
(Cognitive Neuroscience Treatment Research to Improve 
Cognition in Schizophrenia) seek to further understand the 
nature of cognitive impairment in schizophrenia and identify 
new targets for treatment (Nuechterlein et  al., 2004; Carter 
et  al., 2008; Lustig et  al., 2012). Both MATRICS and CNTRICS 
demonstrate the current focus on cognitive impairment associ-
ated with schizophrenia and highlight deficits in attention as 
a core feature of this disorder (Nuechterlein et al., 2008, 2009). 
Attentional impairments are resistant to treatment, precede 
episodes of psychosis, and may contribute to further, higher-
order cognitive impairments (an der Heiden and Häfner, 2000; 
Riedel et al., 2006). There is, therefore, an important unmet need 
to understand the neural mechanisms that contribute to atten-
tional impairment in schizophrenia.
Structural and functional brain abnormalities are commonly 
observed in patients with schizophrenia (Meyer-Lindenberg, 
2010), including ventricular enlargement (Van Horn and 
McManus, 1992), reduced total brain volume (Wright et  al., 
2000), cortical thinning (Schultz et al., 2010), and decreased grey 
matter density (Honea et al., 2005). While the regional specific-
ity of structural alterations in schizophrenia are heterogeneous 
(Honea et al., 2005), the more consistent morphological altera-
tions include enlargement of the ventricles together with grey 
matter loss in amygdala, hippocampus, and parahippocampus 
gyrus (Shenton et al., 2001). In addition, schizophrenia patients 
show impaired attentional performance on continuous per-
formance tests and reduced activation of the dorsolateral pre-
frontal cortex compared with unaffected controls (Chen and 
Faraone, 2001; Yoon et al., 2008).
Dysfunction of the glutamatergic system, specifically 
N-methyl-d-aspartate receptor (NMDAR) hypofunction, has 
been hypothesised to play a central role in schizophrenia 
pathogenesis (Olney et al., 1999; Kantrowitz and Javitt, 2010). 
This hypothesis was developed from the observation that 
NMDAR antagonists (e.g., ketamine and phencyclidine [PCP]) 
could mimic various aspects of disease symptomatology in 
humans (Cosgrove and Newell, 1991; Krystal et al., 1994) and 
exacerbate symptoms in treatment-stabilized schizophrenia 
patients (Lahti et al., 1995; Malhotra et al., 1997). In addition, 
chronic administration of ketamine in humans leads to struc-
tural brain abnormalities and reduces functional connectiv-
ity (Liao et  al., 2010, 2011, 2012), while acutely administered 
ketamine impairs regional activation during cognitive and 
perceptual testing (Honey et  al., 2005a; Deakin et  al., 2008). 
Collectively, these studies suggest a causal contribution of 
NMDA-receptor blockade in mediating many of the morpho-
logical and functional alterations that underlie the pathophys-
iology of schizophrenia (Fusar-Poli et al., 2007; Ellison-Wright 
and Bullmore, 2010).
Several behavioral paradigms are commonly used to assess 
cognitive function in animal models of schizophrenia (Young 
et  al., 2009). One widely-used task is the 5-choice serial reac-
tion time task (5-CSRTT; Carli et al., 1983; Robbins, 2002), which 
was selected by the CNTRICS group as a task with high con-
struct validity in the assessment of attentional impairment 
in schizophrenia (Lustig et  al., 2012). The 5-CSRTT requires 
animals to actively detect and respond to brief visuo-spatial 
stimuli to obtain rewards, thus recruiting elements of sustained 
and divided attention. In contrast, assessment of sensorimotor 
gating (prepulse inhibition [PPI]) reflects a passive form of atten-
tion that enables filtering of irrelevant sensory information 
(Young et al., 2009). Both dimensions of attention are disrupted 
in schizophrenia patients, as well as in experimental animals 
treated with acute PCP (Swerdlow et al., 1994; Chen and Faraone, 
2001; Geyer et al., 2001; Amitai and Markou, 2010).
 Previous imaging studies in rats have assessed functional 
correlates of acutely administered NMDAR antagonists (Gozzi 
et al., 2007; Gozzi et al. 2008a, 2008b; Herdon et al., 2008; Schwarz 
et  al., 2008; Hodkinson et  al., 2012). However, repeated drug 
exposure is thought to more closely model cognitive deficits, 
negative symptoms, and neuropathological processes relevant 
to schizophrenia (Jentsch and Roth, 1999; Morris et  al., 2005; 
Neill et al., 2010, 2013). The present study therefore used a well-
validated sub-chronic dosing regimen to investigate the effects 
of PCP on passive (PPI) and active (5-CSRTT) forms of atten-
tion in the drug-free state. In addition, ex-vivo high-resolution 
microscopy was carried out with voxel-based morphometry to 
investigate perturbations in regional brain morphology and cor-
tical thickness in PCP-treated animals.
Methods and Materials
Animals
Male hooded-Lister rats (n = 40; Charles River; weighing 350 ± 10 g 
at the start of the experiment) were housed in groups of four on 
a 12 hour reversed light cycle (lights on at 19:00 h) in a tempera-
ture-controlled (21 ± 2oC) and humidity-controlled (55 ± 5%) envi-
ronment. Behavioral testing took place during the dark cycle, 
under red lighting. Animals undergoing behavioral experiments 
had free access to food (Special Diet Services) and water until 
one week prior to the beginning of training, where food restric-
tion reduced animal weights to 90% of their free-feeding body 
weight (approximately 16-18g rat chow/rat/day). Food restriction 
continued throughout training and testing, with water availa-
ble ad libitum in the home cage. Experiments were conducted 
in accordance with the UK Animals (Scientific Procedures) 1986 
Act and local university ethical guidelines.
Apparatus
Twelve 5-hole boxes (25 cm x 25 cm aluminium chambers), each 
enclosed within a wooden sound-attenuating cubicle (Med 
Associates) were used. The rear wall of each testing chamber 
was concavely curved and contained five response apertures. 
Each aperture was 2.5 cm2, 4 cm deep, and set 2 cm above floor 
level. Located at the rear of each aperture was a yellow LED 
providing the visual stimulus. An infrared photocell beam fixed 
horizontally at the entrance of each aperture registered nose-
poke responses. Located on the front wall of the test chamber 
was a food magazine that allowed retrieval of the food reward 
(45 mg Rodent Pellet, Sandown Scientific). Interruption of an 
infrared photocell beam at the entrance to the food magazine 
reported the collection of food rewards and triggered the next 
trial. A wall-mounted fan provided ventilation and background 
noise. All twelve chambers were connected to a PC and data 
was acquired using the Whisker control system v2.5 (Cambridge 
Cognition; Cardinal and Aitken, 2010)
PPI of the acoustic startle was assessed in startle chambers 
(Kinder Scientific). Animals were placed in a confinement cham-
ber, beneath which was placed an accelerometer to assess the 
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magnitude of the startle response. Confinement chambers were 
contained within a sound-attenuating chamber, with startle 
stimulus and pre-pulse being delivered by a speaker fixed on 
the sound-attenuating chamber.
Behavioral Procedures
Rats were trained to detect and report the occurrence of a brief, 
1 s visual stimulus presented pseudo-randomly in one of the 
five available apertures following an inter-trial interval (ITI; 5 
s). The procedure was conducted with the house light on, as 
described previously (Bari et al., 2008). Correct detection of the 
visual stimulus within the limited hold (LH; time period follow-
ing the stimulus during which animals can make a response, 
5 s) was reported via a nose-poke in the illuminated aperture 
(correct response), resulting in the delivery of food reward. 
Reward collection initiated the next ITI, during which the ani-
mal was required to attend to the array of visual apertures and 
detect the presentation of the next visual stimulus. A failure to 
respond to the stimulus (error of omission) or responding to an 
aperture where the light was not presented (incorrect response) 
resulted in a 5 s time-out period, whereby the house light was 
extinguished and no food reward was delivered. A  failure to 
wait for the stimulus presentation—i.e. a nose-poke during 
the ITI—was recorded as a premature response and initiated a 
time-out period. Repeat responses in any of the apertures (per-
severative response), while recorded, were not punished. The 
session ended following 100 trials or 30 min, whichever occurred 
first. In previous 5-CSRTT studies, response accuracy and per-
cent correct responding have been used to describe the same 
measure. These two measures are distinguishable, as accuracy 
is calculated independently of omissions while percent correct 
responding is derived from correct, incorrect, and omitted tri-
als. We have used this method of calculating accuracy and per-
cent correct responding, as previously described (Amitai et al., 
2007; Barnes et  al., 2012). Manipulations of basic task param-
eters are an accepted method of increasing 5-CSRTT difficulty 
(Amitai and Markou, 2011). Sessions that included either a vari-
able stimulus duration (1.0, 0.75, 0.5, 0.25 s) or a variable ITI (8, 
6, 4, 2 s) were presented as acute attentional challenges. These 
were presented in a pseudorandom order with 25 trials for each 
variable level.
The acoustic startle reactivity paradigm (see Geyer and 
Swerdlow, 2001) began with a 5 min acclimation period con-
sisting of 65 dB background white noise. Following acclima-
tion, a series of 6 pulse-alone (40 msec burst of 120 dB noise) 
trials were presented. This was followed by 25 trials compris-
ing four distinct trial types: pulse alone (described above) and 
3 prepulse trials. The prepulse trial included a prepulse stimu-
lus (3, 6, or 12 dB above background for 20 ms) that preceded a 
120 sec pulse trial with an inter-stimulus interval of 100 msec. 
These four trial types were presented in a pseudorandom order, 
with 10 pulse-alone trials and 5 of each prepulse trial. The ses-
sion was concluded by the presentation of 5 consecutive pulse-
alone trials. Each trial was interspersed by a variable ITI that 
averaged 15 s.  Percent PPI was calculated as follows: 100-(pp/
po) x 100 in which pp = response during prepulse intensity and 
po = response during pulse only trial.
Behavioral Training
Rats were habituated to the 5-CSRTT chambers for two days 
prior to training, and apertures were illuminated and baited to 
encourage exploration. The training schedule (6 days per week, 
previously described in Bari et al., 2008) started with a stimu-
lus duration (SD) of 120 s. The SD was progressively reduced to 
the final testing criteria of 1 s. Animals progressed when they 
reached a stable level of performance >80% accuracy and <20% 
omissions. The LH was also reduced as the animal acquired the 
task in the same manner as the SD, with the exception that the 
LH reduction stopped at 5 s, therefore giving testing criteria of 1 s 
SD and 5 s LH. Throughout the training period, the ITI and time-
out period remained at 5 s. Rats were deemed trained when they 
had reached stable performance at the final protocol (1 s SD, 5 s 
ITI, 5 s LH) for three consecutive days. The entire training proce-
dure required approximately 12 weeks to complete.
Sub-Chronic PCP Administration
PCP was purchased from Sigma-Aldrich. Animals were adminis-
tered saline (0.9% saline, n = 10) or PCP (5 mg/kg, n = 10) via the 
intra-peritoneal route. The sub-chronic PCP treatment regimen 
consisted of 7 twice-daily (9 AM and 5 PM) injections followed 
by a 7-day washout period, previously shown to produce robust, 
lasting cognitive and social behavioral deficits (reviewed in Neill 
et al., 2010, 2013). During this 14-day period, animals received no 
behavioral training or testing. A separate cohort of animals was 
administered saline (0.9% saline, n = 10) or PCP (5 mg/kg intra-
peritonealy, n = 10) and perfused after a 15-day washout period 
to enable ex-vivo magnetic resonance imaging to be carried out.
Experimental Design
A summary of the timeline of experimental procedures is shown in 
Figure 1. Once trained, all 20 animals were tested on the standard 
version of the 5-CSRTT (SD 1 s; ITI 5 s) followed by two behavioral 
challenge sessions. The variable stimulus duration and ITI chal-
lenge sessions were interspersed with two baseline (i.e., non-chal-
lenge) sessions. Following 5-CSRTT testing, PPI was assessed. After 
the baseline behavioral testing was completed, the sub-chronic 
PCP treatment schedule commenced. To determine treatment 
groups, animals were group-matched based on baseline 5-CSRTT 
performance as well as task-related performance. Animals were 
re-tested on the 5-CSRTT, using standard task parameters, 8 days 
after the last PCP injection. Thereafter, the acute behavioral chal-
lenges (variable SD and variable ITI; 10 and 13  days post-PCP) 
were interspersed with baseline sessions (days 11 and 12) and PPI 
(14 days post-PCP). A separate cohort of 20 animals was adminis-
tered PCP or saline in an identical manner and perfused with 4% 
PFA 15 days post-PCP, prior to high-resolution ex-vivo microscopy.
Magnetic Resonance Imaging
Brains were immersed in FluorInert solution (FC-70, 3M) as a 
susceptibility-matching fluid without any MR signal and scanned 
at 4.7 T using a Bruker PharmaScan 47/16 system with a 20 mm 
birdcage transmit/receive coil (Sawiak et  al., 2009). The pulse 
sequence used was a rapid acquisition with relaxation enhance-
ment sequence with TR/TE 1500/36 ms. Other scan parameters 
included: field of view (3.1 cm × 1.6 cm × 1.2 cm) with a matrix of 
384 × 200 × 150 for an isotropic resolution of 80 µm with 8 averages 
and an echo train length of 10 echoes. Parameters were chosen for 
optimal contrast between grey and white matter for morphometry.
Voxel Based Morphometry
Scans were analyzed using SPM8 following previously estab-
lished methods (Draganski et al., 2004). The unified segmentation 
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algorithm of SPM8 with DARTEL was used as modified by SPM 
Mouse for rat brains (Ashburner and Friston, 2005; Ashburner, 
2007; Sawiak et al., 2013). MR images were corrected for radio-fre-
quency coil inhomogeneity and registered to a stereotactic tem-
plate of the rat brain using SPM8 and SPMMouse (Sawiak et al., 
2009). The resulting maps of grey matter were smoothed with a 
400 µm Gaussian kernel. Treated and control brains were com-
pared using a two-tailed, two-group student’s t-test on a voxel-
by-voxel basis. Regions of the brain with a low grey matter score 
(below 30%) were excluded from the analysis, and areas in the ex-
vivo data where damage had occurred in extraction were masked 
before analysis. To control the type I error rate due to multiple 
comparisons, a voxel-wise height threshold of p < 0.001 was used, 
together with an empirically-derived extent threshold of 603 vox-
els for a corrected family-wise error probability of p < 0.05.
Cortical Thickness
To specifically investigate alterations in cortical morphology, 
we used a voxel-based cortical thickness method (Hutton et al., 
2008), as adapted and validated previously for the rodent brain 
(Sawiak et al., 2012). Briefly, DARTEL registration fields for each 
subject were used to warp a cortical mask drawn on the tem-
plate image to the native space of each animal, where cortical 
thickness values were calculated by integrating streamlines 
found from Laplace’s equation. The resulting maps were then 
assessed using a general linear model. A  two-group student’s 
t-test was used, significant voxels were identified using a height 
threshold of p < 0.001, and type I errors were controlled with a 
family-wise error-adjusted p-value of p < 0.05, using a cluster 
extent threshold established with random field theory (SPM). 
Two-tailed tests were used throughout.
Behavioral Data Analysis
Behavioral data are displayed as mean ± SEM and analyzed using 
Statistica v8 (Statsoft). 5-CSRTT data were analyzed by a two-way 
repeated-measures ANOVA, with day, stimulus duration, ITI, or 
trial bin (first half of session vs. second half of session) as the 
repeated measures, where appropriate, and treatment as a fixed 
factor. To specifically assess post-treatment, between-subject 
performance, a one-way ANCOVA with treatment as the fixed 
factor and pre-treatment performance as the covariate was 
conducted. PPI data were analyzed using a three-way repeated 
measures ANOVA (with day and treatment the fixed factors and 
prepulse intensity the repeated measure). Following global analy-
sis of the behavioral data, planned comparisons (Snedecor and 
Cochran, 1989) were used to assess longitudinal within-subject 
and/or between-subject effects. For interactions at p < 0.1, we also 
examined whether lower-order main effects were detectable after 
subdivision of the interactive variables (Snedecor and Cochran, 
1967). The threshold for statistical significance was set at α = 0.05.
Results
5-CSRTT: Baseline Session
Sub-chronic PCP significantly impaired performance on the 
standard version of the 5-CSRTT (SD 1 s; ITI 5 s; see Table  1). 
However, these effects were less pronounced compared with 
those observed during the challenge sessions reported below, 
and mainly affected the latency of animals to respond correctly 
(day x treatment interaction, F(1,18) = 6.95, p < 0.05). Specifically, 
animals treated with PCP responded more slowly than control 
rats (p < 0.05). Apart from significant main effects of day for cor-
rect responses (F(1,18) = 6.11, p < 0.05) and omissions (F(1,18) = 6.17, 
p < 0.05), no other significant effects were found.
5-CSRTT: Variable Stimulus Duration
PCP-treated rats were markedly impaired with respect to atten-
tional accuracy (%Accuracy) during the variable stimulus dura-
tion challenge session (day x treatment interaction: F(1,18) = 7.79, 
p < 0.05). Thus, the attentional accuracy of PCP rats significantly 
decreased relative to pre-treatment performance and saline 
control animals (p < 0.01; Figure 2A). ANCOVA confirmed a sig-
nificant reduction in response accuracy between control and 
PCP animals (F(1,17) = 9.85, p < 0.01). This impairment was driven 
by a significant increase in incorrect responses (day x treat-
ment interaction, F(1,18) = 8.66, p < 0.01), revealed by a significant 
within-subject increase in incorrect responding in PCP-treated 
animals but not saline-treated animals (p < 0.01; Figure 2B), and 
Figure 1. Experimental timeline. Rats were trained for approximately 3 months on the five-choice serial reaction time task (5-CSRTT). Once trained, behavioral assess-
ment involved standard (SD = 1 s; ITI = 5 s) and challenge (variable SD and ITI) sessions on the 5-CSRTT and PPI. Animals were treated with PCP (n = 10) or saline (n = 10) 
twice daily for 7 days, followed by a 7-day washout period. After the 1-week treatment regimen, animals were re-assessed in the 5-CSRTT during baseline sessions 
and challenge sessions, followed by PPI (A). A separate cohort of animals was administered PCP (n = 10) or saline (n = 10) and perfused with 4% PFA to enable ex-vivo 
microscopy to be carried out. Animals were perfused 15-days post-PCP treatment to coincide with the completion of behavioral testing in the first group (B). Values 
shown are in weeks. BL, baseline 5-CSRTT session; vSD, variable stimulus duration challenge session; vITI, variable inter-trial interval challenge session; PPI, prepulse 
inhibition; d1 - d7, day 1 - day 7.
Barnes et al. | 5
Figure 2. Attentional impairment in rats treated sub-chronically with PCP. Rats were challenged with variable SD (top row) and variable ITI (bottom row) ses-
sions. Response accuracy was reduced in PCP-treated animals in the variable SD session (A). This was mainly attributed to an increase in incorrect responding (B). 
Analysis of performance, as a function of stimulus duration, revealed a reduction in accuracy of PCP-treated animals when presented with stimuli of 1 and 0.75 
s in duration (C). These deficits were restricted to the last half of the session (D). Response accuracy was also reduced in PCP-treated animals when challenged 
during an acute variable ITI session (E), an effect largely driven by an increase in incorrect responding (F). When performance was analyzed as a function of ITI, 
a reduction in accuracy was only evident when animals were presented with a 2 s ITI (G). Accuracy impairments were only evident during the second half of the 
session (H).,Between-subject differences: *p < 0.05 and **p < 0.01. Within-subject differences: #p < 0.05 and ##p < 0.01. Open white columns represent saline control 
animals; open shaded columns represent PCP animals before sub-chronic PCP treatment. Dashed white columns represent saline animals and dashed shaded 
columns represent PCP treated animals after PCP treatment. Open circles represent saline-treated animals and open-squares denote PCP-treated animals. Data 
are mean ± SEM.
Table 1. Summary of Behavioral Performance of Rats on the 5-CSRTT During Baseline (BL), Variable Stimulus Duration (vSD), and Variable ITI
(vITI) Challenge Sessions.).
Pre-treatment Post-treatment
Saline (n = 10) PCP (n = 10) Saline (n = 10) PCP (n = 10)
BL Performance
% Accuracy 84.5 ± 1.6 83.7 ± 2.3 84.5 ± 1.0 80.3 ± 3.2
% Correct 76.4 ± 1.8 77.6 ± 3.4 75.0 ± 1.7 69.7 ± 3.3
% Incorrect 14.1 ± 1.3 14.8 ± 2.0 13.7 ± 0.9 17.0 ± 2.8
% Omission 9.6 ± 1.7 7.6 ± 2.2 11.3 ± 1.6 13.3 ± 1.5
% Premature 8.4 ± 1.8 5.9 ± 1.3 11.2 ± 1.8 9.6 ± 3.3
Correct Lat (s) 0.72 ± 0.06 0.69 ± 0.04 0.68 ± 0.05 0.76 ± 0.05 *,#
Magazine Lat (s) 1.44 ± 0.10 1.40 ± 0.06 1.37 ± 0.09 1.29 ± 0.06
Perseverative 103.2 ± 9.6 157.8 ± 28.0 131.2 ± 11.4 161.8 ± 26.9
vSD Performance
% Accuracy 75.8 ± 1.4 74.8 ± 2.1 77.4 ± 2.1 67.8 ± 2.2 **, ##
% Correct 68.3 ± 1.6 66.2 ± 2.3 67.3 ± 2.3 58.2 ± 3.3
% Incorrect 21.9 ± 1.4 22.3 ± 1.9 19.9 ± 2.1 27.3 ± 1.7 **, ##
% Omission 9.8 ± 1.7 11.5 ± 1.6 12.9 ± 2.8 14.5 ± 2.8
% Premature 10.2 ± 2.2 6.9 ± 1.4 4.8 ± 1.0 6.3 ± 2.4
Correct Lat (s) 0.69 ± 0.05 0.71 ± 0.04 0.71 ± 0.05 0.77 ± 0.05
Magazine Lat (s) 1.36 ± 0.09 1.37 ± 0.04 1.37 ± 0.09 1.36 ± 0.07
Perseverative 128.0 ± 15.7 167.4 ± 32.5 120.0 ± 12.4 149.5 ± 30.7
vITI Performance
% Accuracy 79.8 ± 2.4 79.8 ± 1.7 80.0 ± 2.0 71.8 ± 3.1 *, #
% Correct 63.4 ± 4.0 58.2 ± 3.2 60.1 ± 3.2 52.0 ± 3.5
% Incorrect 15.69 ± 1.7 14.9 ± 1.3 14.7 ± 1.3 19.8 ± 2.0 *, #
% Omission 20.9 ± 3.6 22.1 ± 2.2 25.2 ± 2.6 26.3 ± 3.7
% Premature 30.2 ± 4.1 21.7 ± 2.9 24.3 ± 2.8 28.6 ± 2.7
Correct Lat (s) 0.84 ± 0.03 0.79 ± 0.06 0.84 ± 0.07 0.91 ± 0.05
Magazine Lat (s) 1.35 ± 0.10 1.35 ± 0.4 1.35 ± 0.85 1.30 ± 0.05
Perseverative 144.5 ± 13.9 181.0 ± 36.4 130.2 ± 16.6 171.7 ± 35.5
Behavioral measures are shown as mean ± SEM before (pre-treatment) and after (post-treatment) sub-chronic PCP administration. Within-subject effect, saline or 
PCP pre- vs post-treatment: #p < 0.05 and ##p < 0.01). Between-subject effect, saline vs PCP posttreatment: *p < 0.05 and **p < 0.01).
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a significant post-treatment group difference between saline 
and PCP rats (ANCOVA: F(1,17) = 9.66, p < 0.01). No other significant 
effects were found during this intervention (see Table 1).
Further analysis demonstrated that response accuracy 
declined as the stimulus duration decreased (F(3,54) = 12.47, p < 
0.001). ANOVA revealed a main effect of treatment (F(1,18) = 9.22, 
p < 0.01) and planned comparisons demonstrated that PCP-
treated animals showed significantly reduced attentional accu-
racy when presented with stimuli of 1 and 0.75 sec in duration (p 
< 0.05; Figure 2C). Moreover, attentional accuracy declined over 
the course of the challenge session (trial x treatment interac-
tion, F(1,18) = 5.95, p < 0.05), with response accuracy significantly 
reduced in PCP rats compared with controls during the second 
half of the session (p < 0.01; Figure 2D). Thus, PCP treatment sig-
nificantly impaired the ability of animals to maintain accurate 
performance over the full duration of the session.
5-CSRTT: Variable Inter-Trial Interval
PCP rats also exhibited impaired attentional accuracy when the 
inter-trial interval was made unpredictable, a manipulation that 
taxes sustained attention. Decomposing the near-significant day 
x treatment interaction (F(1,17) = 4.23, p = 0.055) revealed a within-
subject reduction in response accuracy in PCP-treated animals 
but not saline controls (p < 0.05), and a significant post-treatment 
impairment between saline- and PCP-treated animals (F(1,16) = 5.35, 
p < 0.05; Figure  2E). Similar to the effects reported above, PCP-
treated rats made more incorrect responses than saline-treated 
animals (day x treatment interaction, F(1,17) = 3.92, p = 0.06), revealed 
by a significant post-treatment group effect (F(1,16) = 4.75, p < 0.05; 
Figure 2F). No other behavioral variable was significantly affected 
by sub-chronic PCP during this challenge session (Table 1).
Attentional accuracy also significantly declined during the 
variable ITI session (F(3,54)  = 8.58, p < 0.001) and was accompa-
nied by a significant main effect of treatment (F(1,18) = 4.90, p < 
0.05). Based on previous findings (Dalley et al., 2004), a planned 
comparison revealed that response accuracy was significantly 
decreased in PCP-treated rats compared with controls when 
the ITI was 2 s (p < 0.05; Figure  2G). Similar to the findings 
reported for the variable SD session, PCP-treated rats showed 
a decrement in attentional accuracy during the second half of 
the session compared with control animals (trial x treatment 
interaction:, F(1,15) = 8.15, p < 0.05), demonstrated by significant 
within- and between-subject effects during the second block of 
trials (p < 0.01; Figure 2H).
Prepulse Inhibition
Analysis of startle magnitude between the two acoustic star-
tle sessions indicated that both saline and PCP rats exhibited 
habituation to the startle response (F(1,18) = 8.09, p < 0.05; data 
not shown). However, although the level of PPI increased pre-
dictably as the prepulse intensity increased (F(2,72)  = 50.36, p < 
0.001), this was no different between saline and PCP animals 
(Figure 3A and B).
High-Resolution Ex-Vivo Microscopy
The mean cortical thickness of control and PCP rats is shown 
in Figure  4. Significant clusters demonstrating a reduction in 
cortical thickness in PCP rats were found in the lateral soma-
tosensory cortex and insula cortex anteriorly and posteriorly 
bordering the ectorhinal cortex (Figure 4B and C). Qualitatively 
similar differences were observed bilaterally, though the signifi-
cance scores were lower on the right side and did not survive 
correction for multiple comparisons.
Significant reductions in grey matter density were observed 
bilaterally in the anterior cingulate cortex (ACC), ventral stria-
tum (VS), amygdaloid nucleus, and, most prominently, in the 
hippocampal formation of PCP-treated rats compared with 
saline-treated rats (Figure 5). No areas of increased grey matter 
were observed.
Discussion
These findings demonstrate that sub-chronic PCP administra-
tion causes a range of structural abnormalities that localize to 
the hippocampus, ACC, amygdala, insular cortex, and VS. These 
abnormalities were detected up to 15  days after the last PCP 
injection and may contribute to impaired attentional function, 
notably affecting active sustained attention whilst sparing pas-
sive attention in terms of sensorimotor gating. Collectively, these 
findings add specificity to the sequelae of effects produced by 
protracted NMDAR antagonism whilst also revealing significant 
overlaps with the spectrum of cognitive and neural abnormali-
ties found in schizophrenia. In particular, our findings implicate 
NMDAR hypofunction within cortico-amygdalo-hippocampal 
Figure 3. Pre-pulse inhibition of the startle response before (A) and after (B) sub-chronic PCP treatment. It can be seen that PCP had no significant effect on prepulse 
inhibition of the acoustic startle response. A main effect of prepulse effect: *p < 0.001. Open white columns represent saline control animals (n = 10); open shaded 
columns represent PCP animals (n = 10) before sub-chronic PCP treatment. Dashed white columns represent saline control animals; shaded dashed columns represent 
PCP-treated animals after PCP. Data are mean ± SEM.
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circuitry, encompassing the VS and ACC as putative key loci 
underlying attentional dysfunction in schizophrenia.
The present study demonstrates that sub-chronic PCP treat-
ment impairs 5-CSRTT performance in the drug-free state when 
performance is challenged. During the variable SD challenge 
session, PCP rats were significantly less accurate than control 
animals during long SDs. In general, short SDs demand greater 
attention to facilitate target detection (Bushnell, 1998), and 
this manipulation predictably reduced discriminative accuracy 
in both control and PCP rats. The deficit when longer (but not 
shorter) SDs were presented likely represented a floor effect 
with performance in control animals impaired. However, the 
increased attentional demands of this manipulation likely exac-
erbated deficits during the longer SDs, impairing performance 
in the second half of the session. This deficit could perhaps best 
be described as a vigilance decrement, as corroborated by recent 
findings (Barnes et al., 2012). Consistent with this interpretation, 
attentional accuracy also declined in PCP rats on trials where the 
opportunity to respond prematurely was significantly reduced. 
Deficits following this manipulation were only present when 
shortest ITI was presented and again emerged during the second 
half of the session. This variant of the task requires the continu-
ous allocation of finite attentional resources and previously has 
been shown to reveal a vigilance decrement in rats depleted of 
acetylcholine in the prefrontal cortex (PFC) (Dalley et al., 2004). 
In support of our findings, increasing task difficulty by increas-
ing perceptual load has been shown to temporally degrade 
continuous attentional performance in schizophrenia patients 
(Nestor et al., 1990; Mass et al., 2000). Time-on-task deficits have 
also been reported in schizophrenia patients on related tasks of 
sustained attention (Hahn et  al., 2012; Young et  al., 2013). Our 
findings thus indicate that sub-chronic PCP produces deficits in 
sustained attention that resemble a significant component of the 
attentional impairment present in schizophrenia.
Pre-attentive sensorimotor gating, as assessed by PPI, is also 
impaired in schizophrenia (Braff et al., 2001). However, the neu-
ral correlates of PPI are complex, with interactions between sub-
cortical and brainstem circuitry being modulated by a number 
of forebrain structures (Fendt et al., 2001; Swerdlow et al., 2001). 
Grey matter volume changes in several limbic-striatal structures 
have been linked to PPI (Kumari et al., 2005). Our results suggest, 
Figure 4. Average voxel-based cortical thickness in rats treated with PCP. Scale bar 
in mm (A). Areas of significantly reduced cortical thickness in PCP-treated animals 
compared with saline-treated animals; the scale bar shows student’s t-score based 
on 14 degrees of freedom. Results surviving a cluster-extent correction for fam-
ily-wise error p < 0.05 are shown (B). Coronal sections indicating reduced cortical 
thickness in the insular cortex, left somatosensory cortex (S1; C; panel 1), granular 
and dysgranular insular cortex (panel 2), granular, dysgranular insular cortex, and 
ectorhinal cortex (panel 3). Regions identified using Paxinos and Watson (1997).
Figure 5. Coronal sections showing areas of significant differences in grey matter between rats treated with saline and PCP. The horizontal scale bar is 2 mm; the color 
scale shows the student’s t-score. Results shown are significant at a cluster-level corrected family-wise error of p < 0.05. The test performed was two-tailed, but only 
grey matter reductions were observed. ACC, anterior cingulate cortex; VS, ventral striatum; Amyg, amydaloid regions; Hipp, hippocampus.
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however, that while the structural integrity of many of these 
regions may be vulnerable to disruption by sub-chronic PCP, this 
alone is not sufficient to impair PPI. Our findings thus replicate 
previous studies showing PCP to have no effect on PPI in adult 
rats (Martinez et al., 1999; Egerton et al., 2008). However, when 
administered to neonatal rats, PCP has been shown to impair 
PPI in adulthood (Le Pen et al., 2003). The mechanism underly-
ing this presumed neurodevelopmental influence is unclear but 
may involve disruption of GABAergic remodelling during adoles-
cence (O’Donnell, 2012). Despite GABAergic deficits being evident 
in rats following both neonatal and adult PCP administration 
(Jones et al., 2011), the absence of PPI deficits in the present study 
may be attributable to PCP being administered after this criti-
cal period of neurodevelopment (Powell, 2010). Unlike PPI, active 
attentional processing is less reliant on sensory filtering, and 
this may explain why sub-chronic antagonism of NMDAR dur-
ing adulthood selectively impaired sustained, effortful attention.
Our findings show that sub-chronic PCP results in reduced 
grey matter density in several limbic cortico-striatal structures, 
including the amygdala, VS, hippocampus, insular cortex, and 
ACC. Comparable structural abnormalities have been reported 
in schizophrenia (Honea et  al., 2005), affecting the amygdala, 
hippocampus, parahippocampus gyrus, caudate, striatum, and 
ACC (Seidman et al., 1999; Shenton et al., 2001; Chua et al., 2007; 
Williams, 2008; Rametti et  al., 2010; Stegmayer et  al., 2013). 
Cortical thinning in frontal regions (Schultz et  al., 2010) and 
insular cortexes (Pujol et al., 2013) are evident. In addition, grey 
matter deficits in temporal lobe structures, together with struc-
tural and functional deficits in the ACC, predict impaired con-
tinuous attentional performance in schizophrenia (Volz et  al., 
1999; Salgado-Pineda et al., 2004). Moreover, reduced cingulate, 
caudate, and hippocampus volume is evident in patients with 
attentional deficits (Salgado-Pineda et al., 2003), while decreased 
amygdala volume has been linked to first-episode psychosis 
patients (Aas et al., 2012). Interestingly, decreased hippocampal 
and caudate volume has also been reported in relatives of schiz-
ophrenia patients (Bhojraj et al., 2011) whilst structural deficits 
that also include the amygdala underlie attentional dysfunction 
in mania (Sax et al., 1999; Fleck et al., 2012). Along with struc-
tural deficits, schizophrenia is associated with functional discon-
nectivity of several regions, including the ACC, and attentional 
deficits (Honey et at. 2005b). Sustained NMDAR hypofunction 
has recently been shown to compromise functional integra-
tion between several brain regions in the rat, with connectivity 
between frontal and hippocampal structures impaired (Dawson 
et al., 2014). These observations encourage the conclusion that 
the observed structural deficits associated with sub-chronic PCP, 
localized within discrete regions implicated in schizophrenia 
pathology and attentional processing, contributed to impaired 
sustained attention in our study. In addition, our findings impli-
cate NMDAR hypofunction in the spectrum of morphological and 
attentional deficits found in schizophrenia.
Structural brain abnormalities are widely reported in keta-
mine abusers (Liao et al., 2010, 2011; Wang et al., 2013). Although 
these structural alterations appear to be less pronounced than 
those observed in the current study, heterogeneity in terms of 
age, years of ketamine use, and poly-drug abuse may account 
for this variance. Nevertheless, the effects of acute ketamine 
administration and structural deficits associated with chronic 
NMDAR antagonism suggest similar regional specificity to the 
regions implicated in the present study. While we cannot rule 
out PCP-induced neurotoxicity (Olney et al., 1989) as a contribut-
ing mechanism for the structural deficits we observed, several 
investigations suggest this may not be the case. High doses of 
PCP (up to 50 mg/kg) produced neurotoxicity in regions includ-
ing the posterior cingulate/retrosplenial cortex, piriform cor-
tex, olfactory tubercle, and cerebellum (Nakki et al., 1995; Corso 
et al., 1997; Johnson et al., 1998). Animals administered 5 mg/kg 
were indistinguishable from saline-treated animals (Nakki et al., 
1995), or alterations indicative of neurotoxicity were transient 
and restricted to the retrosplenial cortex (Corso et  al., 1997). 
Moreover, female rats displayed increased sensitivity to NMDAR 
neurotoxicity (Olney et al., 1989) and were used in several of the 
studies described above, in contrast to male rats used in the 
current investigation. Importantly, previous investigations with 
lower PCP doses (including one using male rats and an identical 
regimen to ours) did not observe any evidence of PCP-induced 
neurotoxicity (Hajszan et al., 2006; Fattorini et al., 2008). Given 
the treatment regimen used and the absence of structural defi-
cits in the posterior cingulate/retrosplenial cortex, piriform cor-
tex, olfactory tubercle, or cerebellum, it is unlikely the structural 
changes presently described were due to PCP-induced neuronal 
degeneration or apoptosis. A  potential mechanism underpin-
ning our findings may lie with NMDAR antagonists produc-
ing excitatory disinhibition via blockade of NMDAR located 
on GABAergic interneurons (Nakazawa et al., 2012). This effect 
results in increasing activity within limbic cortico-thalamic cir-
cuits (Morris et al., 2005). Persistent GABAergic impairments are 
evident following repeated PCP treatments (Neill et  al., 2010), 
which are associated with reductions in GAD67 and parvalbumin 
expression (Abdul-Monim et al., 2007; Bullock et al., 2009; Jenkins 
et  al., 2010). Furthermore, dendritic spine density reductions 
have also been reported using an identical treatment regimen 
(Hajszan et al., 2006; Elsworth et al., 2011). Therefore, reductions 
in both GABAergic markers and dendritic spine density may 
have contributed to reductions in grey matter and attentional 
deficits observed in the current investigation.
Sustained attentional performance on the 5-CSRTT depends on 
the functional integrity of distinct striatal and frontal brain regions 
coupled with dissociable modulatory influences by the monoam-
ine transmitter systems (Robbins, 2002). Thus, neurotoxic lesions 
of the ACC in rats selectively impair the accuracy of responding 
on this task (Passetti et al., 2002; Chudasama et al., 2003), a deficit 
that is notably sensitive to modulation at the level of the nucleus 
accumbens (Pezze et al., 2009). Moreover, lesions localized to the 
medial striatum, which together with the nucleus accumbens 
overlap with the region of reduced grey matter density in the 
present study, also impair attentional performance on this task 
(Rogers et al., 2001). Although initial reports suggested that the hip-
pocampus was not required for 5-CSRTT performance (Kirkby and 
Higgins, 1998), subsequent investigations in neonatal and adult 
rats have demonstrated a convincing role of the ventral hippocam-
pus in maintaining performance during increased attentional load 
(Le Pen et al., 2003; Abela et al., 2013). These findings resonate with 
the profile of PCP-induced structural abnormalities observed in the 
present study, which likely therefore contributed to the decrement 
in attentional performance on the 5-CSRTT.
In addition to attentional impairment, sub-chronic PCP 
administration produces robust impairments in a number of 
cognitive processes relevant to schizophrenia (for review see 
Neill et al., 2010). For example, PCP disrupts novel object recog-
nition (Grayson et al., 2007), spatial memory on the Morris water 
maze (Didriksen et  al., 2007), attentional set-shifting (McLean 
et  al., 2008), reversal learning (McLean et  al., 2010), and social 
behavior (Snigdha and Neill, 2008). Key neural loci responsible 
for these impairments include the hippocampus (Broadbent 
et al., 2004; Squire et al., 2004), amgydala (Lee et al., 2005), and 
interactions with the fronto-striatal systems (Chudasama and 
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Robbins, 2006; Brooks et  al., 2012). The spectrum of structural 
deficits reported in the present study may, as a result, have 
broader consequences for impaired cognitive processing after 
sub-chronic exposure to PCP and other NMDAR antagonists.
In summary, our findings reveal a collection of structural 
and attentional abnormalities associated with sub-chronic PCP 
administration in rats that may have relevance for schizophre-
nia. In particular, our results implicate NMDAR dysfunction as a 
candidate neural mechanism in the emergence of regional volu-
metric deficits in schizophrenia that may contribute to cognitive 
deficits in schizophrenia.
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